Suppression of mammary-derived growth inhibitor gene expression by growth hormone and insulin-like growth factor I

International Journal of Oncology

Volumn 13, Issue 3, 1998, Pages 577-582

  Huynh, Hung ^a   Beamer, Wesley ^b  

^a MCGILL UNIVERSITY   (Canada)

^b JACKSON LABORATORY   (United States)

Author keywords

Breast cancer; Gene regulation; GH IGF I axis; Tumor suppressor

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; FULVESTRANT; GROWTH HORMONE RELEASING FACTOR; GROWTH INHIBITOR; HUMAN GROWTH HORMONE; MESSENGER RNA; OCTREOTIDE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUS MUTATION; TUMOR SUPPRESSOR GENE;

EID: 0031877045     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.3.577     Document Type: Article

References (52)

1. Dickson RB and Lippman ME: Growth factors in breast cancer. Endocr Rev 16: 559-589, 1995.
2. Gong Y, Ballejo G, Murphy LC and Murphy LJ: Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometria adenocarcinoma cells. Cancer Res 52: 1704-1709, 1992.
3. Grosse RB, Böhmer FD, Binas B, Kurtz A, Spitzer E, Müller T and Zschiesche W: Mammary-derived growth inhibitor (MDGI). In: Genes, Oncogenes and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Dickson RB and Lippman ME (eds). Kluwer Academic Publishers, Boston, pp69-96, 1991.
4. Huynh HT, Larsson C, Narod S and Pollak M: Tumour suppressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res 55: 2225-2231, 1995.
5. Bohmer FD, Kraft R, Otto A, Wernstedt C, Hellman U, Kurtz A, Müller T, Rohde K, Etzold G, Lehmann W, Langen P, Heldin CH and Grosse RB: Identification of a polypeptide growth inhibitor from bovine mammary gland. J Biol Chem 262: 15137-15143, 1987.
6. Spener F, Unterberg C, Borchers T and Grosse RB: Characteristics of fatty acid-binding proteins and their relation to mammary-derived growth inhibitor. Mol Cell Biochem 98: 57-68, 1990.
7. Veerkamp JH, Peeters RA and Maatman RGHJ: Structural and functional features of different types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1081: 1-24, 1991.
8. Bohmer FD, Mieth M, Reichmann G, Taube C, Grosse RB and Hollenberg M: A polypeptide growth inhibitor isolated from lactating bovine mammary gland (MDGI) is a lipid-carrying protein. J Cell Biochem 38: 199-204, 1988.
9. Bohmer F, Lehman W, Schmidt HE, Langen P and Grosse RB: Purification of a growth inhibitor of Ehrlich ascites mammary carcinoma cells from bovine mammary gland. Exp Cell Res 150: 466-476, 1984.
10. Kurtz A, Vogel F, Funa K, Heldin CH and Grosse RB: Developmental regulation of mammary-derived growth inhibitor expression in bovine mammary tissue. J Cell Biol 110:1779-1789, 1990.
11. Nielsen SU and Spener F: Fatty acid-binding protein from rat heart is phosphorylated on Tyr19 in response to insulin stimulation. J Lipid Res 34: 1355-1366, 1993.
12. Wobus AM, Zschiesche W and Grosse RB: Differentiation-promoting effects of mammary-derived growth inhibitor (MDGI) on pluripotent mouse embryonic stem cells. Virchows Arch (B) 59: 339-342, 1990.
13. Binas B, Spitzer E, Zschiesche W, Erdmann B, Kurtz A, Müller T, Niemann C, Blenau W and Grosse RB: Hormonal induction of functional differentiation and mammary derived growth inhibitor expression in cultured mouse mammary gland explants. In vitro Cell Dev Biol Anim 28A: 625-634, 1992.
14. Scholz H, Kohlwein S, Paltauf F, Lezius A and Spener F: Expression of a functionally active cardiac fatty acid-binding protein in the yeast, Saccharomyces cerevisiae. Mol Cell Biochem 98: 69-74, 1990.
15. Phelan MC, Larson C, Baird S, Futreal A, Ruttledge HM, Morgan K, Tonin P, Huynh HT, Korneluk RG, Pollak MN and Narod SA: The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumours. Genomics 34: 63-68, 1996.
16. Huynh HT, Alpert L and Pollak M: Silencing of the mammary derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res 56: 4865-4870, 1996.
17. Huynh H and Pollak M: Stabilization of mammary-derived growth inhibitor mRNA by antiestrogens. Clin Cancer Res 3: 2151-2156, 1997.
18. LeRoith D, Clemmons D, Nissley P and Rechler MM: NIH conference. Insulin-like growth factors in health and disease. Ann Intern Med 116: 854-862, 1992.
19. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P and Baserga R: The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55: 2463-2469, 1995.
20. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252, 1995.
21. Huynh HT, Alpert L and Pollak M: Pregnancy-dependent growth of mammary tumors is associated with overexpression of insulin-like growth factor II. Cancer Res 56: 3651-3654, 1996.
22. Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8: 45-62, 1997.
23. Ruan W, Newman C and Kleinberg D: Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Natl Acad Sci USA 89: 10872-10876, 1992.
24. Yang X, Beamer W, Huynh HT and Pollak M: Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation. Cancer Res 56: 1509-1511, 1996.
25. Pollak MN: Endocrine effects of IGF-I on normal and trans' formed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat (In Press).
26. Welsch CW: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 45: 3415-3443, 1985.
27. Eicher E and Beamer W: Inherited ateliotic dwarfism in mice. Characteristics of the mutation, little, on chromosome 6. J Hered 67:87-91, 1976.
28. Jansson JO, Downs TR, Beamer WG and Frohman LA: Receptor-associated resistance to growth hormone-releasing factor in dwarf 'little' mice. Science 232: 511-512, 1986.
29. Godfrey P, Rahal JO, Beamer WG, Copeland NG, Jenkins NA and Mayo KE: GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat Genet 4: 227-232, 1993.
30. Huynh HT, Tetenes E, Wallace L and Pollak M: In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res 53: 1727-1730, 1993.
31. Murphy LJ, Bell GI, Duckworth ML and Friesen HG: Identification, characterization, and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I. Endocrinology 121: 684-691, 1987.
32. Kleinberg DL, Ruan W, Catanese V, Newman CB and Feldman M: Non-Iactogenic effects of growth hormone on growth and insulin-like growth factor-I messenger ribonucleic acid of rat mammary gland. (Published erratum appears in Endocrinology 127: 1977, 1990) Endocrinology 126: 3274-3276, 1990.
33. Plaut K, Ikeda M and Vonderhaar BK: Role of growth hormone and insulin-like growth factor-I in mammary development. Endocrinology 133: 1843-1848, 1993.
34. Huynh HT and Pollak M: Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 203: 253-259, 1994.
35. Forsyth IA: Growth factors in mammary gland function (Review). J Reprod Fertil 85: 759-770, 1989.
36. Flint DJ, Tonner E, Beattie J and Panton D: Investigation of the mechanism of action of growth hormone in stimulating lactation in the rat. J Endocrinol 134: 377-383, 1992.
37. Arteaga CL: Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 22: 101-106, 1992.
38. Chen WY, Chen NY, Yum J, Washer TE and Kopchick JJ: In vitro and in vivo studies of antagonistic effects of human growth hormone analogues. J Biol Chem 269: 15892-15897, 1994.
39. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z and Schally AV: Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 91: 12298-12302, 1994.
40. Weckbecker G, Tolcsvai L, Stolz B, Pollak M and Bruns C: Somatostatin analogue octreotide enhances the antineoplastic . effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a) anthracene-induced rat mammary carcinomas. Cancer Res 54: 6334-6337, 1994.
41. Weckbecker G, Raulf F, Stolz B and Bruns C: Somatostatin analogs for diagnosis and treatment of cancer (Review). Pharmacol Ther 60: 245-264, 1993.
42. Schally AV: Oncological applications of somatostatin analogues. Cancer Res 48: 6977-6985, 1988.
43. Garel A and Axel R: Selective digestion of transcriptionally active ovalbumin genes from oviduct nuclei. Proc Natl Acad Sci USA 73: 3966-3970, 1976.
44. Pollak M, Polychronakos C and Guyda H: Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9: 889-892, 1989.
45. Setyono-Han B, Henkelman MS, Foekens JA and Klijn GM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47: 1566-1570, 1987.
46. Van Eijck CH, Krenning EP, Bootsma A, Lindemans J, Jeekel J, Reubi JC and Lamberts SW: Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343: 640-643, 1994.
47. Russo IH and Russo J: Hormone prevention of mammary carcinogenesis: a new approach in anticancer research. Anticancer Res 8: 1247-1262, 1988.
48. Malaab SA, Pollak M and Goodyer CG: Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 28: 788-793, 1992.
49. Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B and Margolese R: Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82: 1693-1697, 1990.
50. Huynh HT, Yang X and Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016-1021, 1996.
51. Huynh HT, Yang X and Pollak M: A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the anti-estrogen ICI 182780. Cell Growth Differ 7: 1501-1506, 1996.
52. Huynh HT, Nickerson T, Yang X and Pollak M: Regulation of insulin-like growth factor I receptor by the pure antiestrogen ICI 182,780. Clin Cancer Res 2: 2037-2042, 1996.